Studies molecular changes linked to heart failure in patients
Studies molecular signals in people with heart failure to find markers of disease progression.
Key facts
- Who runs it
- University of Zurich
- Where
- Zurich, SwitzerlandSee the site
- Trial code
- Registry title
- Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 1 Feb 2025
- Expected to end
- 30 Nov 2031
- Type of study
- Observational, 3 groups
- Record updated
- 25 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure. It studies blood and other samples and clinical data to find molecular signs linked to how heart failure starts and progresses.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Heart failure diagnosed according to the ESC Heart Failure Guidelines.
Main reasons for not taking part
- Active cancer, or past cancer with ongoing treatment such as chemotherapy, radiotherapy or immunotherapy
- Autoimmune or systemic inflammatory diseases
- Acute infections such as sepsis or pneumonia
- Chronic infections with effects on the whole body, such as HIV or hepatitis B/C with raised transaminases
- Not able to give written informed consent
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Female and Male, age ≥18 years at screening
- Diagnosis of Heart Failure according to ESC Heart Failure Guidelines
- Ability to understand the requirements of the study and to provide informed consent
- Willingness to undergo follow-up
Who cannot take part
- Patients will be excluded if they meet any of the following conditions:
- Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy)
- Autoimmune or systemic inflammatory diseases
- Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B/C with elevated transaminases); Other exclusion criteria:
- Age<18 years old
- Inability to provide written informed consent
Where in Switzerland
- University Hospital of ZurichZurich, SwitzerlandContact: Jan A Kleeberger, MDTaking people
About the trial
What the trial wants to find out
The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients.
Read full original descriptionShow less
The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.
The 3 groups in the trial
- Heart Failure with reduced ejection fraction (HFrEF)
LVEF \<40%
- Heart Failure with preserved ejection fraction (HFpEF)
LVEF \>50%
- Heart Failure with mildyly reduced ejection fraction (HFmrEF)
LVEF \>40% and \<50%
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling: the BIOCARDIUM-HF Study
- Plain-language title
- Studies molecular changes linked to heart failure in patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 September 2026